ImmuPharma Soars On Avion Lupus Deal
Validates Management Faith In Lupuzor
Executive Summary
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
You may also be interested in...
Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.